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What FactorS are aSSociated With increaSing chargeS For Major 
joint rePlaceMentS BetWeen 2008 and 2011?
Chiu G.R, Dong X., Wang Z., Meckley L.M., Miyasato G.
Trinity Partners, LLC, Waltham, MA, USA
Objectives: This study measured the association between hospital characteristics 
and changes in hospital charges for major joint replacement (MJR). MethOds: 
2008 and 2011 hospital charge and reimbursement data were obtained from MJR 
inpatient Medicare claims. Multivariate linear regression models were used at the 
hospital level to regress the percent change in hospital charges on hospital charac-
teristics which included hospital demographics and MJR patient summary meas-
ures. Independent variables represented both baseline 2008 and change in value/
status quantities. Results: The analysis included 3,016 hospitals. In multivariate 
models, many hospital characteristics were significantly associated with the per-
cent change in charges. Hospital type and census region were significantly related 
to percent change in charges. Specifically, Government and Non-Profit hospitals 
experienced smaller charge increases than Proprietary hospitals (-5.5% and -4.5% 
respectively, p< 0.0001). Compared to the Northeast, the West, South, and Midwest 
experienced 5.5%, 4.4%, and 3.3% increases in charges on average (p≤ 0.001), while 
the Midwest, West, and South were not statistically significantly different from each 
other (p> 0.05). Also, a one-day increase in the average length of stay was associ-
ated with an average charge increase of 6.7% (p< 0.0001). Overall, the final model 
accounted for 9% of the total variance. cOnclusiOns: Hospital characteristics, 
such as the region and type, as well as changes to average length of stay between 
2008 and 2011 were strong predictors of percent change in average charge for MJR. 
While several other factors were also statistically significantly related to change 
in charges for MJR, small effect sizes were not practically meaningful. The small 
percent of variance explained by the model leads us to conclude there are other 
factors not captured by Medicare data that are additionally responsible for growth 
in health care costs.
PMS80
health care Utilization coStS and Medication USe PatternS oF 
tUMor necroSiS Factor (tnF) inhiBitorS aMong texaS Medicaid 
PatientS diagnoSed With rheUMatoid arthritiS
Oladapo A.1, Barner J.C.2, Richards K.2, Rascati K.L.2, Lawson K.A.2, Novak S.3, Harrison D.J.4
1Baxter Healthcare Corporation, Westlake Village, CA, USA, 2The University of Texas at Austin, 
Austin, TX, USA, 3Austin Outcomes Research, Inc., Austin, TX, USA, 4Amgen, Inc, Thousand Oaks, 
CA, USA
Objectives: To evaluate health care costs and medication use patterns (persistence, 
discontinuation and switching) in patients with rheumatoid arthritis (RA) on etaner-
cept (ETN), infliximab (IFX) or adalimumab (ADA) in Texas Medicaid. MethOds: 
Prescription and medical claims for Texas Medicaid beneficiaries (18-63 years) 
with an RA diagnosis (ICD-9-CM code 714.0x) without claims for a biologic agent 
in the 6-months pre-index (July 1, 2003 to December 31, 2010) were analyzed over 
an 18-month study period between July 1, 2003 and August 31, 2011 (6-month 
pre- and 12-month post-index) based on their index biologic (ADA, ETN, or INF). 
The primary outcomes were 1-year persistence, discontinuation, switching and 
health care costs (RA-related and TNF inhibitor costs) to Texas Medicaid post-index, 
adjusted to 2011 US dollars using the medical consumer price index. Cohorts were 
constructed using propensity score (PS) matching controlling for baseline differ-
ences in demographics and clinical characteristics. Results: After PS matching, 
822 patients (n= 274/biologic group) comprised the final sample. The mean age (±SD) 
was 48.9 (±9.8) years, and the majority (69.2%) were between age 45 and 63, Hispanic 
(53.7%) and female (88.0%). Post-index mean (±SD) total health care costs were 
$16,477 (±$9,228), RA-related costs were $13,713 (±$8,309) and TNF inhibitor costs 
were $12,195 (±$8,517). For each cost variable (total health care, RA-related and TNF 
inhibitor costs), costs incurred by patients on ETN were significantly lower (p< 0.01) 
than those incurred by ADA patients but significantly higher (p< 0.01) than those 
incurred by IFX patients. Persistence to index TNF inhibitor therapy and likelihood 
to switch or discontinue were comparable among groups. Duration of medication 
use (i.e. persistence) prior to switching or discontinuation of index therapy was also 
comparable among groups. cOnclusiOns: The data suggest comparable medica-
tion use patterns but significantly different health care utilization costs among 
Texas Medicaid RA patients on ETN, IFX or ADA.
PMS83
Utilizing nordic regiStrieS to SUPPort health econoMicS reSearch 
in rheUMatic diSeaSeS
Miller H.
Karolinska Institutet, Stockholm, Sweden
Objectives: Rheumatic diseases are often characterized by pain and disability. 
Many pharmaceuticals are available for their treatment and a considerable number 
of health economic(HE) studies have been published. Nordic countries maintain 
long-term comprehensive disease and drug registries. HE analyses, particularly 
those which are based on registry-data, can provide important information for 
health care decision makers. The primary objective of this study is to systematically 
review HE analyses of rheumatic diseases which utilize Nordic registry-data, and 
to provide a descriptive and critical analysis of this strategy. MethOds: Published 
literature was identified by searching the following databases: MEDLINE; EMBASE; 
Cochrane Library and Health Economic Evaluations Database; and PubMed. Search 
terms were pertinent to rheumatic diseases and HE. One reviewer screened and 
subsequently extracted data from studies which fulfilled inclusion/exclusion cri-
teria. References and citation search was done on included studies. Results: 45 
HE studies utilized Nordic registry-data. Studies were relevant to Sweden(n= 26), 
Norway(n= 11), Finland(n= 4) and Denmark(n= 4). Study types were modeling(n= 13), 
costing(n= 8), work/productivity(n= 6), quality-of-life(n= 13), and a combination 
of HE outcomes(n= 5). Registry data was used within the studies to characterize 
patients in regards to clinical(n= 29), demographic(n= 20), utility(n= 18) and cost/
drugs (70.75%). The most commonly prescribed anti-rheumatic drugs were NSAIDs 
and Analgesics (75.60%), DMARDs (20.40%) and Corticosteroids (4.00%). Multiple 
logistic regression analysis showed that females (OR: 0.55; 95% CI: 0.32-0.95), indi-
viduals aged group 18 to 64 years (OR: 0.48; 95% CI: 0.29-0.78) were less likely to 
receive anti-rheumatic drugs, whereas those seeking care from rheumatologists 
(OR: 4.38; 95% CI: 2.19-8.77) and those with multiple previous visits (OR: 1.43; 95% 
CI: 1.26-1.62) were more likely to receive anti rheumatic drugs. cOnclusiOns: 
Most (7 out of 10) visits for the RA involved use of anti-rheumatic drugs. Drug use 
patterns varied across age, gender, physician specialty, and previous use of health 
care. Further research is needed to evaluate the variation across drug classes 
for RA.
PMS77
relationShiP BetWeen the dUration oF rheUMatology Practice 
exPerience and likelihood oF USe and PercePtion toWardS 
BioSiMilarS in rheUMatoid arthritiS (ra) arena
Narayanan S.
Ipsos Healthcare, Columbia, MD, USA
Objectives: To assess the relationship between duration of rheumatology practice 
experience and rheumatologist perception towards biosimilars and the likelihood of 
use of biosimilars to manage RA patients in the European Union (EU), Brazil, Japan 
and China. MethOds: A multi-country cross-sectional survey was conducted in 
top-5 EU countries (UK/Germany/Spain/France/Italy), Brazil, Japan and China in 
April/May 2013 using an online physician panel in the respective geographies; rheu-
matologists were randomly selected for survey participation to be geographically 
representative in select countries/regions. Surveys assessed the rheumatologist 
perceptions of biosimilars in terms of factors that would prevent them from using 
biosimilars among their biologic-eligible RA patients, and their likelihood of use of 
biosimilars. Summary statistics are reported across the markets, stratified by years 
of rheumatology-practice-experience. Results: 173 rheumatologists participated 
in the survey (5EU-58%, Brazil-23%, Japan-11% and China-9%); years of experience 
practicing rheumatology (across the markets) was: < = 10yrs:26%, 11-20yrs:42%, 
> 20yrs:32%. Mean RA patient-volume/year based on rheumatology-practice-expe-
rience was: < = 10yrs:264, 11-20yrs:323, > 20yrs:270. Likelihood of prescribing a bio-
similar product to eligible RA patients differed by rheumatology-practice-experience 
(< = 10yrs/11-20yrs/> 20yrs): definitely-13%/13%/5%; highly likely-27%/42%/39%; may 
be/not sure-44%/36%/38%; less/not likely-16%/10%/18%. Perceived duration of use of 
biosimilars in a small group of patients before prescribing it in larger scale was (by 
rheumatology-practice-experience < = 10yrs/11-20yrs/> 20yrs): 1-2yrs:53%/56%/43%, 
3-5yrs:16%/11%/14%, 6-10yrs:2%/1%/2%, > 10yrs:4%/4%/5%; not-sure:24%/28%/36%. 
Key factors noted by rheumatologists that would prevent them from using bio-
similars were (by rheumatology-practice-experience < = 10yrs/11-20yrs/> 20yrs): 
Doubts in similarity to original molecule(56%/63%/59%), inadequate safety/effi-
cacy profile/data(47%/57%/52%), lack of long-term data(42%/39%/57%), lack of 
national guidelines recommending the use of biosimilars(40%/38%/34%), lack of 
data from local country/market(40%/31%/25%), lack of trust/confidence in manu-
facturer(24%/25%/27%). cOnclusiOns: Rheumatologists perceptions varied based 
on their practice-experience; those with < = 10yrs of practice-experience reported 
the least likelihood of prescribing biosimilars, and a higher proportion of them cited 
national treatment guidelines and lack of data from local country/market among 
key reasons preventing biosimilar use.
PMS78
coMPariSon oF clinical characteriSticS oF PatientS With 
rheUMatoid arthritiS (ra) receiving a Biologic MonotheraPy and 
Biologic coMBination theraPy in the United StateS
Narayanan S.1, Lu Y.2, Hutchings R.2, Baynton E.2
1Ipsos Healthcare, Columbia, MD, USA, 2Ipsos Healthcare, London, UK
Objectives: To assess the clinical characteristics of patients with RA who received 
a biologic monotherapy (Mono) and biologic combination therapy (Combo: 
Biologic+DMARDs) in the US. MethOds: A multi-country multi-center medical 
chart-review study of RA patients was conducted between Nov2012-Jan2013 among 
physicians (mainly rheumatologists) in hospitals and private practices to collect 
de-identified data on patients who were recently treated with a biologic as part of 
usual care. Physicians were screened for duration of practice (3-30 yrs) and patient 
volume (incl. > 2RA biologic patients/week) and recruited from a large panel to be 
geographically representative of the US. Eligible patient charts (> 5) were randomly 
selected from a sample of prospective patients visiting each center/practice dur-
ing the screening period. Physicians abstracted patient diagnosis, treatment pat-
terns/dynamics and patient symptomatology/disease status. This analysis focused 
on patients currently on Mono and Combo biologics. Results: 919 eligible RA 
patients were included in the analysis; Mono patients: 353 (38%), Combo patients: 
566 (62%). Patient characteristics included (Mono/Combo): mean age:47.4/57.8; 
female:50%/61%; mean weight(Kg):75.7/78.0; top-3 comorbidities: obesity(17%/20%), 
dyslipidemia(14%/22%, depression/anxiety:9%/16%. Time between RA diagnosis 
and recent office visit (Mono/Combo):77.1/78.5months; number of biologic-lines 
of therapy received (Mono/Combo): 1st-line-80%/70%, 2nd-line-15%/20%, > = 3rd-
line-5%/11%; top-4 biologics used across the two patient groups were: adalimumab/
etanercept/infliximab/abatacept. Among patients with data-availability, current lab 
& disease-severity measures were (Mono/Combo): ESR(mm/h)-23.7/25.0; CRP(mg/
dl)-2.6/3.4; rheumatoid factor (positive%):38%/54%; anti-CCP (positive%):31%/45%; 
overall disease-stage per physician-judgment: mild-67%/62%, moderate-29%/33%, 
severe-4%/5%; mean-HAQ:0.7/0/9; mean-DAS28:2.3/3.0; mean tender joint count: 
2/3/3.4; mean swollen joint count:1.4/2.5. cOnclusiOns: In this cohort of RA 
patients in the US, over 60% of Mono and Combo patients had mild disease per 
physician judgment and a majority of them were on 1st line treatment; lab meas-
ures and joint counts indicated only slightly higher disease burden among Combo 
patients. Impact of specific biologic treatments on observed patterns and the need 
for therapeutic sequencing may warrant scrutiny.
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This study aims to detect and clarify signals of serious skin reactions associated with 
benzodiazepine anticonvulsant therapy in the FDA Adverse Event Reporting System 
(FAERS). MethOds: Cases reported to FAERS between 1997 and 2012 were retrieved. 
The MedDRA Preferred Terms were used to define serious skin reactions. Individual 
anticonvulsant benzodiazepines were identified by generic names. Empirical Bayes 
Geometric Mean (EBGM) with 95% confidence interval (EB05-EB95) were calculated 
as disproportionality measures. Drug-event combinations with EB05≥ 2 were con-
sidered signals that warrant further review. Results: 4,411 reports of serious skin 
reactions were submitted for all anticonvulsant agents. 6.3% were for benzodiaz-
epines (279), corresponding to: clobazam (33), clonazepam (54), clorazepate (41), 
diazepam (82), and lorazepam (69). Signals were detected for clorazepate (EBGM 9.6 
EB05-EB95 7.4-12.4) and clobazam (EBGM 8.7 EB05-EB95 6.4-11.5). Disproportional 
reporting was found for other benzodiazepines, albeit didn’t reach signal threshold: 
diazepam (EBGM 2.3 EB05-EB95 1.9-2.8), lorazepam (EBGM 2.2 EB05-EB95 1.8-2.7), and 
clonazepam (EBGM 1.5 EB05-EB95 1.2-1.9). Eighty one (29%) reported serious skin 
events were fatal, corresponding to: clobazam (7), clonazepam (12), clorazepate (16), 
diazepam (30), and lorazepam (16). Most of reported events listed patient exposure 
to ≥ 2 concomitant drugs at event occurrence time. cOnclusiOns: Anticonvulsant 
therapy with benzodiazepines, particularly clobazam and clorazepate, might be 
associated with serious skin reactions. In concordance with FDA’s recommenda-
tion, patients should seek immediate help when dermal signs and symptoms are 
appeared and alternative anticonvulsant agent should be considered by prescribers. 
Signal evaluation activities are required to further characterize this risk.
Pnd2
natUral hiStory oF PatientS With tUBeroUS ScleroSiS coMPlex 
related renal angioMyoliPoMa
Cappell K.A.1, Song X.2, Liu Z.3, Eynullayeva E.1, Gregory C.1, Prestifilippo J.3, Charles H.4, 
Hulbert J.5, Bissler J.J.6
1Truven Health Analytics, Ann Arbor, MI, USA, 2Truven Health Analytics, Cambridge, MA, USA, 
3Novartis, East Hanover, NJ, USA, 4NYU Radiology Associates, New York, NY, USA, 5Urologic 
Physicians, Edina, MN, USA, 6St. Jude Pediatric Research Hospital, Memphis, TN, USA
Objectives: This retrospective study examined the temporal relationship of diag-
nosis, treatment, health care utilization, and clinical outcomes in patients with 
Tuberous Sclerosis (TSC)-related renal angiomyolipoma in the US. MethOds: 
Patients with ≥ 1 diagnosis of TSC (ICD-9-CM 759.5) and angiomyolipoma (ICD-9-CM 
223.0 and other codes) were extracted from the MarketScan® Commercial Database 
1/1/2000 - 3/31/2013. Patients were followed from the first diagnosis of TSC or angio-
myolipoma (index date) until inpatient death or end of study follow-up. During the 
follow-up, proportion of patients with each event and days from index date to event 
(among those with the event) were reported. An innovative graph was explored to 
describe the natural history of events in this population. Results: The final sample 
consisted of 605 patients (mean age 26.8): 225 patients age< 18 (mean age 9.8, 55% 
female, median follow-up 3.4 years) and 380 patients age≥ 18 (mean age 36.9, 73% 
female, median follow-up 2.2 years). In patients < 18, 87% had TSC diagnosis before 
angiomyolipoma (angiomyolipoma was diagnosed 25.7 months after TSC on aver-
age), 2.8% had complete nephrectomy (8.5 months after index date); emergency 
room (ER) visit, 61% (16.6 months); inpatient admission, 48% (17.0 months); chronic 
kidney disease (CKD), 12% (32.3 months); embolization, 11% (36.2 months); end 
stage renal disease (ESRD), 1.3% (40.9 months); and 1.4% partial nephrectomy (42.0 
months). In patients ≥ 18, 56% had TSC diagnosis before angiomyolipoma (angiomy-
olipoma was diagnosed 16.9 months after TSC), ER visit, 56% (9.9 months); inpatient 
admission, 50% (11.3 months); partial nephrectomy, 7.9% (11.9 months); complete 
nephrectomy, 11.4% (13.9 months); CKD, 23% (15.1 months); embolization, 19% (17.1 
months); and ESRD, 5.3% (20.1 months). cOnclusiOns: This study suggested that 
time from a TSC diagnosis to an angiomyolipoma diagnosis was long and sometimes 
was preceded with ER visits, hospitalizations and surgeries. The innovative graphing 
of natural history can help raise disease awareness in TSC.
Pnd3
real-liFe eFFectiveneSS oF natalizUMaB in relaPSing-reMitting 
MUltiPle ScleroSiS (rrMS): a regiStry analySiS
Danko D.1, Manca A.2, Mor Z3, Csepany T4
1Corvinus University of Budapest, Budapest, Hungary, 2University of York, Heslington, York, UK, 
3Ideas Solutions, Hungary, 4University of Debrecen, Debrecen, Hungary
Objectives: To assess real-world effectiveness, based on registry data, of natali-
zumab in multiple sclerosis (MS) patients with highly active relapsing-remitting MS 
(RRMS). MethOds: Phase IV, observational, retrospective, multi-center database 
analysis on data from the period January 2009 – January 2013. Statistical analy-
ses were performed using Kaplan-Meier and Cox PH regression. Inclusion criteria 
comprised adults aged ≥ 18 with high disease activity with rapidly evolving severe 
RRMS or a relapse despite treatment with beta-interferon or glatiramer acetate. The 
main outcome measure was change from annualized baseline relapse rate (ARR), 
with secondary endpoints comprising sustained disability progression and improve-
ment at 12/24 months, and change in the mean Expanded Disability Status Scale 
(EDSS). Change from baseline ARR comprised ARR absolute values, relative reduc-
tion (percentage), and percentage of patients remaining relapse-free. Analyses were 
presented using frequency tables, crosstabs, graphics and, for EDSS survival analysis 
was conducted. Subgroup analyses were conducted for age, gender and prior treat-
ment received. Results: A total of 216 individuals (72% of whom females) were 
included in the study. Mean age at onset of MS was 27 years, 29 years at diagnosis, 
38 years at start of natalizumab therapy. A significant decrease in mean ARR was 
seen after 12 months compared to baseline (N= 216; Δ = 0.76; p-value< 0.001), and 
between the first and second years of treatment (N= 208; Δ = 0.06; p-value= 0.030). 
There was no significant variation across subgroups. Mean EDSS changed from 3.26 
at baseline to 3.02 at 12 months and 3.16 at 24 months. No new safety concerns 
were noted. cOnclusiOns: Natalizumab treatment in Hungary was associated 
with two-year effectiveness as shown by reduced ARR and stabilized EDSS over the 
observation period. These results are important for decision-makers striving to 
burden of disease(n= 17). Registry-data was used in 3 studies to validate/assess 
generalizability. All modeling studies combined registry with non-registry-data (e.g. 
RCT). cOnclusiOns: Registries provide a rich source of information on real-world 
patients which are being incorporated into health economic analyses. Although 
Nordic registry-data is being utilized in HE studies, many analyses important to HE 
are not represented. These preliminary findings suggest that HE should continue to 
broaden the use and application of registry-data in the field of rheumatic disease. 
Given the gap in data required for an economic-evaluation (e.g. modeling), research-
ers must continue to be aware of potential issues associated with the synthesis of 
RCT and registry-data.
PMS84
PreliMinary reSUltS oF MUltidiSciPlinary SySteMatic FolloW-UP oF 
Fragility FractUreS in orthoPaedic clinic
Fernandes J.1, Delisle J.1, Perreault S.2, Beaumont P.1, Gagnon S.1, Giroux M.3, Jodoin A.1, 
Laflamme Y.1, Leduc S.1, MacThiong J.M.1, Malo M.1, Maurais G.1, Nguyen H.3, Parent S.1, 
Ranger P.1, Raynauld J.P.R.4, Rouleau D.1, Troyanov Y.1
1Hôpital du Sacré Coeur de Montréal, Montreal, QC, Canada, 2Université de Montréal, Montréal, 
QC, Canada, 3Hôpital Jean Talon, Montreal, QC, Canada, 4Institut de Rhumatologie de Montréal, 
Montreal, QC, Canada
Objectives: Despite the major health care impact worldwide of fragility fracture, 
there are few systems in place to identify and capture subjects after a fragility frac-
ture to ensure appropriate assessment and treatment to reduce future fracture risk 
and adverse outcomes. We implemented a multidisciplinary systematic follow-up 
of fragility fractures to close the care gap. MethOds: We recruited 543 subjects 
over 40 years of age who sustained a fragility fracture at the orthopaedic clinic of 
Hôpital du Sacré-Cœur de Montréal or Hôpital Jean-Talon hospital from July 2010 
to 2013. Demographic and clinical data were assessed over 18-months of follow-up. 
We analysed data of patients who have completed at least 18 months of follow-up 
(women n= 99; men n= 16). We described demographic data, BMD, perceived compli-
ance to treatment, and subsequent fracture rates. We assessed the effect on bone 
markers and vitamin D levels using T-test. Results: Mean age was at 61 years. 
The common fracture site was the wrist (40%) followed by the ankle and proximal 
humerus (13%), vertebrae (10%) and hip (7%). Close to 41.7% of women and 20% of 
men had already sustained a previous fragility fracture. At 18 months, 10.1% of 
women and 6.3% of men had already sustained a new fracture. High CTX-1 levels 
(> 0.3 ng/mL) dropped from 46.7% to 21.4% for women and 61.5% to 23.1% for men 
after 18 months of treatment (p< 0.01). Low Vitamin D levels (< 80 nmol/L) increased 
from 63% to 87.5% for women and 16.7% to 83.3% for men (p< 0.00001). Women and 
men perceived they were still persistent and adherent to treatment at 18 months in 
90% and 88% of the time, respectively. cOnclusiOns: Better diagnostic tools and 
systematic management of the fragility fractures and compliance monitoring can 
lower the refracture rates in the long term in this at-risk population.
PMS85
trendS in dMard treatMent FolloWing the introdUction oF a 
rheUMatoid arthritiS ManageMent QUality MeaSUre
Wilson K.L., Johnston S.S.
Truven Health Analytics, Bethesda, MD, USA
Objectives: In 2005, a quality measure was added to the Healthcare Effectiveness 
Data and Information Set (HEDIS) that quantifies the proportion of rheumatoid 
arthritis (RA) patients who receive disease modifying anti-rheumatic drug (DMARD) 
therapy in a given year. This study describes annual trends in the HEDIS RA manage-
ment quality measure among commercially- and Medicare supplemental-insured 
U.S. RA patients from 2005 to 2012. MethOds: This was a retrospective observa-
tional study based on U.S. administrative claims data. Patients selected for study 
during a given measurement year were aged ≥ 18 years, had continuous insurance 
enrollment throughout the year, and had two outpatient claims, on different days, 
with a diagnosis of RA (ICD-9-CM codes 714.0, 714.1, 714.2, 714.81). Receipt of a 
biologic or non-biologic DMARD therapy was assessed annually from 2005 to 2012. 
Bivariate statistics were used to test for differences across the years. Results: 
Annual sample sizes averaged ~95,000 RA patients. From 2005 to 2012, the RA qual-
ity measure was stable at approximately 83% of RA patients receiving DMARD 
treatment. Biologic DMARD utilization increased from 32% in 2005 to 39% in 2012 
(p< 0.001), whereas use of non-biologic DMARDs decreased slightly from 74% to 72% 
(p< 0.001). Among the subset of patients aged ≥ 65 years with Medicare Supplemental 
insurance, the RA quality measure was slightly lower at approximately 78% receiving 
DMARD therapy. Fewer RA patients with Medicare Supplemental insurance received 
biologic DMARDs, however, utilization increased from 23% in 2005 to 29% in 2012 
(p< 0.001). In the same time period, non-biologic DMARD use decreased from 73% to 
69% (p< 0.001). cOnclusiOns: Since the 2005 introduction of the HEDIS RA man-
agement quality measure, increases in the use of biologic DMARD therapy were 
offset by decreases in the use of non-biologic DMARD therapy. Findings suggest 
potential room for improvement in the quality of care for RA patients.
neUrological diSorderS – clinical outcomes Studies
Pnd1
coMParative PharMacovigilance analySiS oF BenzodiazePine 
anticonvUlSant theraPy and SerioUS Skin eventS
Ali A.K.
Eli Lilly and Company, Indianapolis, IN, USA
Objectives: In late 2013, the FDA announced to the public that clobazam is linked 
to serious skin events, including Stevens-Johnson syndrome (SJS), toxic epidermal 
necrolysis (TEN), and acute generalized exanthematous pustulosis (AGEP), and con-
sequently approved changes to clobazam label and medication guide. However, no 
comparative pharmacovigilance analysis was conducted for other anticonvulsant 
benzodiazepines, including clonazepam, clorazepate, diazepam, and lorazepam. 
